A

Abivax

Organization

Heard in 1 episode across 1 show since Oct 2026

Abivax SA is a clinical-stage biotechnology company developing treatments for chronic inflammatory diseases by harnessing the body’s natural regulatory mechanisms to modulate immune responses. Its research focuses on therapeutic approaches involving microRNA and immune regulation.

Learn more

Episodes

1
across 1 show

First heard

Oct 2026

Expert statements

2
2 positive

Episodes per month

Public PodLume episodes featuring it, over the last year.

Show the data
MonthEpisodes
Nov 20250
Dec 20250
Jan 20260
Feb 20260
Mar 20260
Apr 20260
May 20260
Jun 20260
Jul 20260
Aug 20260
Sep 20260
Oct 20261

What experts have said about Abivax

2 statements · 2 positive

  1. Matthew CloutierPositiveOct 10, 2026· Breaking Biotech

    Abivax may be a better buy around the mid-$80s than at $140.

    “I think maybe now that the stock has settled around the mid 80s or so, it's probably a better time to buy now than obviously when it was in 140.”

    Listen at 20:09

    Open the episode · 118 - End of Week Wrap up - Oct 9, 2026
  2. Chloe MelleyPositiveJun 30, 2026· Stock Movers

    Abivax could become a prime takeover target for large pharmaceutical companies

    “it could be potentially a prime takeover target for some big pharmaceutical companies”

    Listen at 1:46

    Open the episode · Abivax Soars, Siemens Energy Up, Mowi's Net Loss
Filter the statements →

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

1 episode featuring Abivax, newest first